Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Uncontrolled, Phase I Dose Escalation Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in Patients With Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

NCT06547528 is registered in ClinicalTrials.gov with Ono Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06547528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06547528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Uncontrolled, Phase I Dose Escalation Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in Patients With Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
October 1, 2023
Completion date
April 30, 2029
Enrollment
108 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory t cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma